Clinical Trials on Multiple Myeloma(MM) in Italy

Total 961 results

Mario Boccadoro

Active, not recruiting

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)

MULTIPLE MYELOMA (MM)

Italy
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Multiple Myeloma (MM)

United States, Italy, Israel, Germany, Japan, Spain, Australia, Norway
AbbVie

Completed

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI)

Multiple Myeloma (MM)

United States, Argentina, Australia, Brazil, Canada, Croatia, Czechia, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovenia, Spain, Taiwan, Turkey
Novartis Pharmaceuticals

Completed

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Italy, Australia, Germany, Spain, France, Japan, United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Pfizer

Recruiting

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases (MUST)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

Italy
Azienda Ospedaliera Universitaria Senese
Janssen-Cilag S.p.A.

Recruiting

Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM)

Myeloma Multiple

Italy
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Multiple Myeloma

United States, Italy
Gruppo Italiano Studio Linfomi

Unknown

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Multiple Myeloma

Italy
Azienda Ospedaliera San Giovanni Battista

Unknown

Hematopoietic Stem Cell Transplantation in Myeloma

Multiple Myeloma

Italy
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
EMN Research Italy

Active, not recruiting

A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) (ISABEL)

Relapsed Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Terminated

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients (D-MP)

Myeloma

Italy
Azienda Ospedaliera Universitaria Mater Domini,...
Associazione Italiana per la Ricerca sul Cancro

Completed

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment (LNA-i-miR221)

Advanced Solid Tumor | Hepatocarcinoma | Multiple Myeloma, Refractory

Italy
Novartis Pharmaceuticals

Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Italy, Germany, Singapore, Australia, United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Non-Hodgkin Lymphoma | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma

United States, Germany, Italy
Fondazione EMN Italy Onlus

Completed

RMPT for Relapsed/Refractory Multiple Myeloma (RMPT)

Multiple Myeloma

Italy
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Oncopeptides AB

Terminated

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

Relapsed and/or Relapsed-refractory Multiple Myeloma

United States, Netherlands, Denmark, Sweden, Italy
Janssen-Cilag Ltd.

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (REALiTEC)

Relapsed/Refractory Multiple Myeloma (RRMM)

France, Denmark, Israel, Spain, Italy, Germany, Sweden
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

Smouldering Myeloma

Netherlands, Norway, Czechia, Italy
University Of Perugia

Recruiting

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

Lymphoma | Acute Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Acute Lymphoid Leukemia | Other Hematologic Malignant Neoplasms

Italy
Bristol-Myers Squibb
Abbott

Terminated

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Newly Diagnosed, Previously Untreated Multiple Myeloma

United States, Poland, Italy, Greece
Sanofi

Completed

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Plasma Cell Myeloma

France, Germany, Italy, Spain
Gruppo Italiano per lo Studio del Mieloma Multiplo

Completed

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Multiple Myeloma

Italy
National Cancer Institute (NCI)

Completed

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States, Italy
Molecular Partners AG

Completed

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma in Relapse

Poland, Italy, Germany, Denmark, Czechia, Austria
European Myeloma Network
Fondazione EMN Italy Onlus

Completed

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CCD)

Multiple Myeloma

Italy
Mario Boccadoro

Completed

Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients (MMpredict)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Multiple Myeloma

Italy
Italfarmaco

Terminated

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Italy
Genenta Science
IRCCS San Raffaele

Terminated

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Multiple Myeloma

Italy
Gruppo Italiano Studio Linfomi

Completed

A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Multiple Myeloma

Italy
Stichting European Myeloma Network
Fondazione EMN Italy Onlus

Active, not recruiting

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Multiple Myeloma

Italy
Azienda Ospedaliera San Giovanni Battista

Completed

Serum Free Light Change in Multiple Myeloma

Multiple Myeloma

Italy
Azienda Ospedaliera San Giovanni Battista

Unknown

Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

Multiple Myeloma

Italy
Università Politecnica delle Marche

Completed

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Multiple Myeloma

Italy
Stichting European Myeloma Network
Janssen, LP

Recruiting

European Myeloma Network (EMN) Sample Project (EMN36)

Multiple Myeloma | Smoldering Multiple Myeloma | Plasma Cell Leukemia | MGUS | Extramedullary Myeloma

Italy, Austria, Czechia, Greece, Serbia
Mario Boccadoro

Completed

STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Multiple Myeloma

Italy
European Myeloma Network
Fondazione EMN Italy Onlus

Completed

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Multiple Myeloma

Italy
European Myeloma Network
University of Turin, Italy

Completed

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (CPD)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Multiple Myeloma

Italy
Azienda Ospedaliera San Giovanni Battista

Unknown

Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma

Multiple Myeloma

Italy
Regina Elena Cancer Institute
University of Rome Tor Vergata; Campus Bio-Medico University; Sant'Eugenio Hospital...

Recruiting

Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma (TEDROMM)

Multiple Myeloma

Italy
University of Turin, Italy

Recruiting

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Multiple Myeloma

Italy

3

Subscribe